The multinational phase 2 study on “A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis” tested the efficacy and safety of cenicriviroc (CVC) in adults with nonalcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease, and liver fibrosis. Results show CVC having significant antifibrotic benefit at year 1 and no worsening of steatohepatitis, warranting phase 3 development of the drug (Hepatology. 2017 Aug 17. doi: 10.1002/hep.29477. [Epub ahead of print])
As the principal investigator of the sole Asian site in this study, our key investigator Prof Vincent Wong welcomes anyone interested in future collaboration in this field of research. Prof Wong is an expert in non-alcoholic fatty liver disease with a particular interest in the non-invasive assessment and treatment of chronic liver diseases.